CG Oncology (CGON) Research & Development (2023 - 2026)

CG Oncology has reported Research & Development for 4 years, with the latest figure at $43.7 million in Q1 2026.

• For the quarter ending Q1 2026, Research & Development rose 59.21% year-over-year to $43.7 million; the trailing twelve-month figure through Mar 2026 stood at $132.9 million (up 43.9% YoY), and the FY2025 full-year result was $116.6 million, up 42.07% from the prior year.
• Research & Development for Q1 2026 stood at $43.7 million, up from $30.0 million in the prior quarter.
• The five-year high for Research & Development was $43.7 million in Q1 2026, with the low at $7.8 million in Q1 2023.
• Historically, Research & Development has averaged $22.2 million across 4 years, with a median of $19.6 million in 2024.
• Annual changes were most pronounced in 2024 — Research & Development surged 119.46% — and 2025, when it rose 11.78%.
• CG Oncology's Research & Development stood at $16.3 million in 2023, then soared by 64.01% to $26.8 million in 2024, then increased by 11.78% to $30.0 million in 2025, then jumped by 45.97% to $43.7 million in 2026.
• The last three Research & Development figures came in at $43.7 million (Q1 2026), $30.0 million (Q4 2025), and $27.9 million (Q3 2025), per Business Quant data.